Mylan's trastuzumab, a generic version of Roche Holding's Herceptin indicated for treatment of breast cancer, has been unanimously recommended for approval by an FDA advisory committee. Regulatory authorities in Europe, Australia and Canada are also reviewing the drug.
FDA panel unanimously recommends Mylan's breast cancer generic
Sign up for Specialty Pharmacy SmartBrief
News affecting the specialty pharmacy industry
Get the intelligence you need: news and information that is changing your industry today, hand-curated by our professional editors from thousands of sources and delivered straight to your inbox.